Cost-utility analysis of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease in Thailand

doi:10.4254/wjh.123353

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(3)

(4)

(0)

(18)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Translational Research

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Oct 27, 2026; 18(10): 123353
Published online Oct 27, 2026. doi: 10.4254/wjh.123353

Full Size Figure Download Figure

Figure 3 Probabilistic sensitivity analyses. A: Cost-effectiveness plane showing incremental cost (THB) on the vertical axis against quality-adjusted life year (QALY) gained on the horizontal axis; B: Cost-effectiveness acceptability curve for semaglutide compared with usual care; C: Cost-effectiveness acceptability curve for liraglutide compared with usual care. In the cost-effectiveness acceptability curves, the vertical axis represents the probability of being cost-effective, and the horizontal axis shows willingness-to-pay (WTP) values. The dashed gray line represents the WTP threshold (THB/QALY gained). QALY: Quality-adjusted life year; THB: Thai baht; WTP: Willingness-to-pay.

Citation: Limwongse S, Chatpattanasiri P, Phuphuang P, Tungthaweethong K, Sutheerayongprasert K, Aunprom-Me W, Kositamongkol C, Phisalprapa P. Cost-utility analysis of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease in Thailand. World J Hepatol 2026; 18(10): 123353
URL: https://www.wjgnet.com/1948-5182/full/v18/i10/123353.htm
DOI: https://dx.doi.org/10.4254/wjh.123353

Limwongse S, Chatpattanasiri P, Phuphuang P, Tungthaweethong K, Sutheerayongprasert K, Aunprom-Me W, Kositamongkol C, Phisalprapa P. Cost-utility analysis of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease in Thailand. World J Hepatol 2026; 18(10): 123353 [DOI: 10.4254/wjh.123353]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.